Dyne Q3 Loss Widens to $193.6M; Cash of $1.13B Funds Runway Into Q2 2028
DYN sits 33% above its 52-week low of $14.
Summary
Dyne reported a wider Q3 2026 net loss of $193.6 million on sharply higher R&D, while $1.134 billion in cash and securities funds operations into the second quarter of 2028 — past the January 2027 z-rostudirsen PDUFA date.
Key Events · Earnings and Guidance · DYN
-
Q3 Loss Widens on R&D Build
Net loss was $193.6 million for Q3 2026 versus $108.0 million a year earlier, and the nine-month net loss reached $493.0 million versus $334.3 million. R&D rose to $161.7 million from $97.2 million, driven by z-rostudirsen manufacturing and FORZETTO trial activity.
-
Cash Runway Into Q2 2028
Cash, cash equivalents and marketable securities totaled $1.134 billion at September 30, 2026, which management says funds operating expenses, debt service and capex into the second quarter of 2028.
-
July Offering and Hercules Tranche
A July 2026 follow-on sold 21,045,000 shares for net proceeds of about $404.9 million, and the third $50.0 million Hercules tranche was drawn in June 2026, lifting principal debt to $200.0 million.
-
Debt Covenants Start July 2027
The Hercules loan carries a minimum cash covenant of 40% of outstanding principal beginning July 1, 2027, waived while market capitalization exceeds $1.65 billion, plus a revenue covenant once FDA approval occurs.
Analysis · DYN · Life Sciences
The balance sheet is the real story here: $1.134 billion in cash and securities, topped up by a $404.9 million July offering and a $50 million Hercules tranche, funds operations into the second quarter of 2028. That runway covers the January 21, 2027 PDUFA date for z-rostudirsen and the first-quarter 2027 ACHIEVE registrational cohort readout for z-basivarsen, so the company does not need to raise equity into either binary event. The trade-off is a heavier cost base — R&D nearly doubled year over year as Dyne scales manufacturing and clinical work for z-rostudirsen and z-basivarsen — and $200 million of debt with covenants that begin testing in July 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $18.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $14.00 to $27.31. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.